Fertility clinic Sydney IVF has obtained stem cells from an Australian embryo, which it will make available to stem cell researchers. [ + ]

Norwood Abbey Ltd [ASX:NAL NASDAQ:NABYF] is close to snatching victory from the jaws of a hostile London investment market, announcing today that its subsidiary Norwood Immunology will list next Wednesday on London’s Alternative Investment Market (AIM), selling 15 million shares and raising AUD$15 million. [ + ]

A Sydney endocrinologist says athletes who inject themselves with the illegal drug Equigen put their lives and careers at risk for no benefit. [ + ]

Canberra-based anti-viral drug developer Biotron has completed acute toxicity tests of its lead anti-HIV drug candidates in mice and found their toxicity levels are within acceptable limits. [ + ]

Adelaide biotech Bionomics (ASX:BNO, BNOOA, US OTC:BMICY) will present new evidence for the therapeutic promise of several molecular antagonists for its proprietary drug target BNO69 in the US today. [ + ]

North Ryde proteomics technology and research company Proteome Systems will list on the ASX later this year at a valuation of only $160 million, after sceptical fund managers baulked at a share price proposal that would have valued it at $300 million. [ + ]

The US Food and Drug Administration has approved Brisbane-based Xenome’s Investigational New Drug (IND) submission for its Xen2174 pain killer. [ + ]

Australian Cancer Technology ("AustCancer") (ASX:ACU) has finalised due diligence on its US$5 million acquisition of Alabama-based vaccine developer Galenica Pharmaceuticals. [ + ]

The Cooperative Research Centre for Polymers (CRC-P) has won a CRC innovation award for the development and commercialisation of a polymer cable that will change fire protection around the world.

Acyte Biotechnology, a spin-out from the University of New South Wales, is to team up with Swiss biopharmaceutical giant Serono to develop recombinant proteins using Acyte's mammalian cell expression technology. [ + ]

Life Therapeutics -- formerly known as Gradipore (ASX:GDP) -- is aiming toestablish a Level 1 American Depository Receipt (ADR) program, in readiness for a Nasdaq. [ + ]

Alabama-based Galenica Pharmaceuticals has delighted its prospective new owner, Sydney oncology specialist Australian Cancer Technology(ASX:ACU), by announcing an agreement with New York's Memorial Sloan-Kettering Cancer Centre to evaluate Galenica's promising immunity enhancer GPI-0100 in several Phase II clinical trials. [ + ]

Prostate Cancer Foundation chief executive Leslie Michelson is turning to eBay to raise research dollars as baby boomers approach the danger age when the disease -- the second-leading cause of cancer deaths in US males -- is most likely to strike. [ + ]

The outlook for biotech IPOs dimmed further last Friday, as Senomyx cut the price of its offering for the second time in as many days and Momenta Pharmaceuticals reducing its estimated price range. [ + ]

Adelaide epilepsy specialist Bionomics (ASX:BNO) has validated its promising genetic test for severe myoclonic epilepsy of infancy (SMEI) by successfully screening a large cohort of children diagnosed with severe epilepsy. [ + ]